Antioxidant supplementation and cancer prevention

JAMA

Volumn 301, Issue 18, 2009, Pages 1877-1878

  Bosland, Maarten C ^a   McCormick, David L ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b IIT RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; SELENOMETHIONINE; ANTINEOPLASTIC AGENT; SELENIUM;

CANCER PREVENTION; CARCINOGENESIS; CHEMOPROPHYLAXIS; DRUG EFFICACY; LETTER; PRIORITY JOURNAL; PROSTATE CANCER; PUBLICATION; ANIMAL; DIET SUPPLEMENTATION; DRUG SCREENING; HUMAN; NEOPLASM; NOTE; PUBLISHING;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; DIETARY SUPPLEMENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; PUBLICATION BIAS; SELENIUM; VITAMIN E;

EID: 65549157814     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.628     Document Type: Letter

References (5)

1. Gann PH. Randomized trials of antioxidant supplementation for cancer prevention: first bias, now chance-next, cause. JAMA. 2009;301(1):102-103.
2. Clark LC, Combs GF Jr, Turnbull BW, et al; Nutritional Prevention of Cancer Study Group. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial [published correction appears in JAMA. 1997;277(19):1520]. JAMA. 1996;276(24):1957-1963.
3. Bosland MC, Johnson WD, Steele VE, Lubet RA, Kelloff GJ, McCormick DL. Prostate cancer chemoprevention efficacy evaluation of combined administration of L-selenomethionine + vitamin E in a rat model. Proc Am Assoc Cancer Res. 2000;41:339-340.
4. Bosland MC, Horton L, Lasano S. Alpha-tocopherol does not protect against prostate cancer but promotes mammary cancer in male NBL rats treated with testosterone and estradiol-17-beta. Proc Am Assoc Cancer Res. 2006;47:925-926.
5. Ozten Kandas N, Lasano S, Bosland MC. Selenomethionine does not protect against prostate cancer in male NBL rats treated with testosterone and estradiol-17β. Proc Am Assoc Cancer Res. 2007;48:6.